Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Apellis Pharmaceuticals (Nasdaq: APLS) announced management will participate in webcast fireside chats at two investor conferences: Citi 2025 Global Healthcare Conference on December 2, 2025 at 2:30 p.m. ET and Evercore 8th Annual Healthcare Conference on December 3, 2025 at 2:10 p.m. ET.
Live webcasts will be posted on the company’s Investors and Media > Events and Presentations webpage. A replay will be available for approximately 30 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction – APLS
On the day this news was published, APLS gained 4.32%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:
Citi’s 2025 Global Healthcare Conference
Date/Time: Tuesday, December 2, 2025 at 2:30 p.m. ET
Evercore 8th Annual Healthcare Conference
Date/Time: Wednesday, December 3, 2025 at 2:10 p.m. ET
The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 30 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.
Investor Contact:
Eva Stroynowski
ir@apellis.com
617.938.6229
FAQ
When will Apellis (APLS) present at the Citi 2025 Global Healthcare Conference?
What time is Apellis (APLS) scheduled at the Evercore 8th Annual Healthcare Conference?
Where can investors watch the Apellis (APLS) conference webcasts on December 2025?
How long will the replay of Apellis (APLS) conference webcasts remain available?
Will Apellis (APLS) provide replays if I miss the December 2–3, 2025 webcasts?
